McGill IBD logo
Donate

Research Activities During the Fellowship

Osamah Abu Hawi/Mohammad Alsaeid
  1. IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management? Alsaeid M, Abu Hawi O, Bessissow T, Lakatos PL.J Clin Med. 2026 Jun 6;15(12):4408. doi: 10.3390/jcm15124408.PMID: 42355576 Free PMC article.
Ivanna Candel
  1. Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.World J Gastroenterol. 2025 Dec 28;31(48):114355. doi: 10.3748/wjg.v31.i48.114355.PMID: 41480329 Free PMC article.
Alessandro Pedicelli
  1. Personalizing IL-23 Inhibitor Therapy in IBD: Current Evidence and Future Directions in Therapeutic Drug Monitoring and Dose Optimization. Pedicelli A, Bessissow T, Afif W.J Clin Med. 2025 Oct 22;14(21):7471. doi: 10.3390/jcm14217471.
  2. Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis. Niyigena E, Hoffert Y, Afif W, Pedicelli A, Roblin X, Hanžel J, Papamichael K, Kobayashi T, Elens L, Wang Z, Ferrante M, Verstockt B, Vermeire S, Vande Casteele N, Battat R, Dreesen E.J Crohns Colitis. 2026 Mar 10;20(3):jjag029. doi: 10.1093/ecco-jcc/jjag029.PMID: 41873130
Paraskevi Tselekouni
  1. A 3D Alginate-Gelatin Co-Culture Model to Study Epithelial-Stromal Interactions in the Gut. Tselekouni P, Mohseni-Garakani M, Papa S, Kim SY, Avramoglu RK, Wertheimer MR, Ajji A, Lakatos PL, Rosenzweig DH.Gels. 2026 Jan 13;12(1):70. doi: 10.3390/gels12010070.PMID: 41590095 Free PMC article.

Your donations help deliver specialized and quality care to people with inflammatory bowel disease (IBD) in Quebec.

Your generosity benefits the IBD clinics at the Montreal General Hospital, the Montreal Children's Hospital and the Jewish General Hospital.

Donate